March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA (finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82 cm version of its Symphony 16F catheter.

March 17, 2025 – Ostial Corp., a privately held medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, has acquired the Wavella technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical, marking a strategic expansion in the coronary and peripheral markets, with product offerings now in the inpatient and office-based settings.

March 17, 2025 — GE HealthCare recently launched the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.

March 11, 2025 — CareDx, Inc. – The Transplant Company – recently announced that AlloSure is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant.

Both indications are approved by the New York State Clinical Laboratory Evaluation Program, demonstrating that AlloSure has met the most rigorous validation standards for laboratory developed tests (LDTs).